Clinical evidence plays a critical role in Japan’s reimbursement process, demonstrating a medical device’s safety, efficacy, and clinical benefits. MHLW and Chuikyo use this evidence to assess the device’s therapeutic value, cost-effectiveness, and alignment with NHI criteria. Robust clinical data, including trial results and real-world outcomes, is essential for reimbursement approval.
